Monthly 140 mg erenumab injections are a safe and effective treatment for patients with nonopioid chronic migraine and medication overuse headaches.

Novartis and Amgen could submit their new monthly migraine injection with regulators next year, after the drug succeeded in a second late-stage trial. They announced positive topline results ...

A new migraine medication - one of the first bespoke drugs for decades - appears to work well even when others have failed, researchers have said . Erenumab is a monthly injection that might soon ...

Administered by monthly injection, the drug works by blocking a protein receptor in the brain, preventing a peptide that may trigger migraines from attaching to its target. During trials ...

Of the 68 patients who completed the study, 40 (59%) experienced a 50% reduction in monthly ... that pericranial injection of BTX, 25 U, is effective for the treatment of migraine.

They randomly received either monthly subcutaneous injections of either Aimovig 140mg ... had nearly three-fold higher odds of having their migraine days cut by at least 50%, with more than ...

This protein makes blood vessels dilate, which can lead to inflammation and a migraine. Studies show the drug reduces the ...

In patients with migraine, erenumab was safe and tolerable and effectively reversed migraine deterioration during treatment pauses.

One class of drugs has already found success in treating the painful, disorienting and common attacks. Excitement is building about a slew of additional drug targets.